Lm vaccines against the tumor antigens HER260 and PSA (prostate-specific antigen)61 generate potent antitumor immunity, while Lm vaccines against other tumor antigens including PAP (prostatic acid phosphatase)10 and mesothelin43 exhibited limited immunogenicity. This evidence concerns the gene PROS1 and neoplasm.